. Author manuscript; available in PMC: 2015 Apr 1.

Published in final edited form as: Breast Cancer Res Treat. 2014 Mar 2;144(3):591–597. doi: 10.1007/s10549-014-2891-0

Table 3. Multivariate model for 12-month CRA (n = 124).

Characteristic	OR	95 % CI	p value
AMH	0.83	0.58–1.20	0.32
Age	1.20^a	1.10–1.33	0.0003
Race (white vs. other)	1.65	0.38–7.17	0.50
Received bevacizumab (yes vs. no)	2.54	0.75–8.56	0.13
Tamoxifen use (yes vs. no)	0.66	0.20–2.13	0.49

CRA chemotherapy-related amenorrhea, AMH anti-mullerian hormone

For every 1 year increase in age, there was a 20 % increase in the odds of developing 12-month CRA